Department of Chemistry, University of Oxford, Oxford, OX1 3TA, United Kingdom.
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, K7L 3N6, Canada.
Sci Rep. 2019 Sep 20;9(1):13608. doi: 10.1038/s41598-019-49264-0.
β-Lactamases are a major threat to the clinical use of carbapenems, which are often antibiotics of last resort. Despite this, the reaction outcomes and mechanisms by which β-lactamases degrade carbapenems are still not fully understood. The carbapenem bicyclic core consists of a β-lactam ring fused to a pyrroline ring. Following β-lactamase-mediated opening of the β-lactam, the pyrroline may interconvert between an enamine (2-pyrroline) form and two epimeric imine (1-pyrroline) forms; previous crystallographic and spectroscopic studies have reported all three of these forms in the contexts of hydrolysis by different β-lactamases. As we show by NMR spectroscopy, the serine β-lactamases (KPC-2, SFC-1, CMY-10, OXA-23, and OXA-48) and metallo-β-lactamases (NDM-1, VIM-1, BcII, CphA, and L1) tested all degrade carbapenems to preferentially give the Δ (enamine) and/or (R)-Δ (imine) products. Rapid non-enzymatic tautomerisation of the Δ product to the (R)-Δ product prevents assignment of the nascent enzymatic product by NMR. The observed stereoselectivity implies that carbapenemases control the form of their pyrroline ring intermediate(s)/product(s), thereby preventing pyrroline tautomerisation from inhibiting catalysis.
β-内酰胺酶对碳青霉烯类药物的临床应用构成了重大威胁,而碳青霉烯类药物通常是最后才使用的抗生素。尽管如此,β-内酰胺酶降解碳青霉烯类药物的反应结果和机制仍未完全了解。碳青霉烯类药物的双环核心由β-内酰胺环与吡咯烷环融合而成。β-内酰胺酶介导β-内酰胺开环后,吡咯烷可能在烯胺(2-吡咯烷)形式和两个差向异构亚胺(1-吡咯烷)形式之间相互转化;以前的晶体学和光谱学研究报告了在不同β-内酰胺酶水解的情况下,这三种形式都存在。正如我们通过 NMR 光谱学所展示的那样,所测试的丝氨酸β-内酰胺酶(KPC-2、SFC-1、CMY-10、OXA-23 和 OXA-48)和金属β-内酰胺酶(NDM-1、VIM-1、BcII、CphA 和 L1)都将碳青霉烯类药物降解为优先生成Δ(烯胺)和/或(R)-Δ(亚胺)产物。Δ产物的快速非酶互变异构化会阻止 NMR 对新生酶促产物的归属。观察到的立体选择性意味着碳青霉烯酶控制其吡咯烷环中间体/产物的形式,从而防止吡咯烷互变异构抑制催化作用。